Akut mieloid leukémia (AML): vizsgálatok itt: Kína
226 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleDEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML
- Where
- Kunming
- Életkor
- 18 év to 65 év
- People
- 291
- Run by
- The Second Affiliated Hospital of Kunming Medical University
See details and how to joinNCT07712848 - Korai 1. fázisNot yet taking people in KínaClinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia
- Where
- Guangzhou
- Életkor
- 3 év to 75 év
- People
- 18
- Run by
- Zhujiang Hospital
See details and how to joinNCT07696481 - 1/2. fázisTaking peopleSingle Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
- Where
- Guanzhou
- Életkor
- 18 év to 60 év
- People
- 40
- Run by
- Zhujiang Hospital
See details and how to joinNCT05270200 - 1. fázisTaking peopleStudy of IBR733 Cell Injection in Acute Myeloid Leukemia
- Where
- Suzhou
- Életkor
- 18 év to 74 év
- People
- 18
- Run by
- Imbioray (Hangzhou) Biomedicine Co., Ltd.
See details and how to joinNCT06234904 - 1. fázisTaking peopleAnti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
- Where
- Nanchang
- Életkor
- 18 év to 70 év
- People
- 18
- Run by
- iCell Gene Therapeutics
See details and how to joinNCT07668557 - 2. fázisNot yet taking people in KínaStudy on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 148
- Run by
- Shen yang
See details and how to joinNCT07664839 - 1/2. fázisTaking peopleLuspatercept for CIA in AML
- Where
- Guangzhou
- Életkor
- 18 év to 60 év
- People
- 40
- Run by
- Guangdong Second Provincial General Hospital
See details and how to joinNCT07663864 - 2/3. fázisCsak meghívásosComparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
- Where
- Hangzhou
- Életkor
- 15 év to 65 év
- People
- 450
- Run by
- First Affiliated Hospital of Zhejiang University
See details and how to joinNCT07651163 - 2/3. fázisCsak meghívásosComparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
- Where
- Hangzhou
- Életkor
- 18 év to 65 év
- People
- 267
- Run by
- First Affiliated Hospital of Zhejiang University
See details and how to joinNCT07651176 - 2. fázisNot yet taking people in KínaSHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS
- Where
- Suzhou
- Életkor
- 18 év to 65 év
- People
- 180
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07575412 - No phaseTaking peopleHaplo-Cord HSCT for AML/MDS
- Where
- Beijing, Chengdu, Fuzhou, Guangzhou
- Életkor
- 14 év to 60 év
- People
- 82
- Run by
- Fujian Medical University Union Hospital
See details and how to joinNCT07588360 - No phaseNot yet taking people in KínaVA Induction and Bridging Transplantation for Hypoplastic/Secondary AML
- Where
- Suzhou
- Életkor
- 18 év and over
- People
- 50
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07635485 - No phaseTaking peopleSymptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors
- Where
- Hangzhou
- Életkor
- 8 év to 18 év
- People
- 600
- Run by
- The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07450872 - 1. fázisTaking peopleAllogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML
- Where
- Beijing
- Életkor
- 18 év to 70 év
- People
- 27
- Run by
- Peking University People's Hospital
See details and how to joinNCT07617285 - 2. fázisTaking peopleIvosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 20
- Run by
- Ruijin Hospital
See details and how to joinNCT07607418 - 1. fázisTaking peopleOptimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia
- Where
- Beijing, Chengdu, Shanghai
- Életkor
- 1 év to 70 év
- People
- 27
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT06326021 - 1/2. fázisTaking peopleA Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
- Where
- Hanzhou
- Életkor
- 18 év and over
- People
- 133
- Run by
- Sunshine Lake Pharma Co., Ltd.
See details and how to joinNCT05133882 - 2/3. fázisTaking peopleVABu Conditioning in Elderly AML HSCT
- Where
- Suzhou
- Életkor
- 60 év and over
- People
- 20
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07583888 - 1/2. fázisTaking peopleVenetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
- Where
- Tianjin
- Életkor
- 14 év and over
- People
- 23
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06611839 - 2. fázisTaking peopleEfficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML
- Where
- Tianjin
- Életkor
- 14 év to 60 év
- People
- 380
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06635681 - 1/2. fázisTaking peopleEfficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
- Where
- Shenzhen
- Életkor
- 18 év to 75 év
- People
- 10
- Run by
- Shenzhen University General Hospital
See details and how to joinNCT07584889 - 2. fázisTaking peopleA Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
- Where
- Beijing
- Életkor
- 14 év to 75 év
- People
- 160
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT06928376 - 1. fázisTaking peopleEfficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy
- Where
- Fuzhou
- Életkor
- 18 év to 70 év
- People
- 90
- Run by
- Fujian Medical University Union Hospital
See details and how to joinNCT07551037 - 4. fázisTaking peopleStudy of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).
- Where
- Fuzhou
- Életkor
- 18 év to 65 év
- People
- 100
- Run by
- Fujian Medical University Union Hospital
See details and how to joinNCT07561892 - 2. fázisNot yet taking people in KínaSHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS
- Where
- Suzhou
- Életkor
- 15 év to 60 év
- People
- 160
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07562568